» Articles » PMID: 20658822

Effect of High-dose Nicotine Patch on the Characteristics of Lapse Episodes

Overview
Journal Health Psychol
Specialty Public Health
Date 2010 Jul 28
PMID 20658822
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Nicotine patch improves treatment outcomes, but lapses are still common. To understand the process of relapse on patch, we investigated differences in the antecedents (withdrawal, setting, triggers) of lapse episodes experienced on high-dose (35 mg) nicotine patches versus placebo.

Design: Participants were smokers who lapsed during a randomized, double-blind trial of active patches (n = 100) versus placebo (n = 85). Participants used electronic diaries to monitor their smoking, affect, and activities in real time for 5 weeks during their cessation attempt.

Results: We analyzed 490 lapse episodes (active: 266; placebo: 224). Lapses on nicotine patch were characterized by significantly lower positive affect and higher negative affect than placebo lapses. Participants treated with high-dose patch were also significantly more likely to lapse in situations involving little or no craving. Situational antecedents of lapses on patch resembled those on placebo.

Conclusion: The results suggest that treatment with patch may set a higher threshold for affective stimuli to provoke lapses, but does not change the proximal cues that trigger lapses. This suggests that behavioral relapse-prevention strategies developed for unmedicated smokers should also apply to those treated with nicotine patch.

Citing Articles

Nicotine replacement treatment, e-cigarettes and an online behavioural intervention to reduce relapse in recent ex-smokers: a multinational four-arm RCT.

McRobbie H, Phillips-Waller A, El Zerbi C, McNeill A, Hajek P, Pesola F Health Technol Assess. 2020; 24(68):1-82.

PMID: 33270009 PMC: 7750867. DOI: 10.3310/hta24680.


Nicotine replacement therapy versus control for smoking cessation.

Hartmann-Boyce J, Chepkin S, Ye W, Bullen C, Lancaster T Cochrane Database Syst Rev. 2018; 5:CD000146.

PMID: 29852054 PMC: 6353172. DOI: 10.1002/14651858.CD000146.pub5.


Examination of the mechanism of action of two pre-quit pharmacotherapies for smoking cessation.

Ferguson S, Walters J, Lu W, Wells G, Schuz N BMC Public Health. 2015; 15:1268.

PMID: 26689281 PMC: 4687305. DOI: 10.1186/s12889-015-2596-2.


Nondaily smokers' experience of craving on days they do not smoke.

Shiffman S, Dunbar M, Tindle H, Ferguson S J Abnorm Psychol. 2015; 124(3):648-59.

PMID: 26052617 PMC: 4624293. DOI: 10.1037/abn0000063.


Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.

Kowalczyk W, Phillips K, Jobes M, Kennedy A, Ghitza U, Agage D Am J Psychiatry. 2015; 172(8):760-7.

PMID: 25783757 PMC: 6233893. DOI: 10.1176/appi.ajp.2014.14081014.